XLO - Xilio Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$98.00
DETAILS
HIGH:
$98.00
LOW:
$98.00
MEDIAN:
$98.00
CONSENSUS:
$98.00
UPSIDE:
1087.88%
About Xilio Therapeutics, Inc. (https://www.xiliotx.com)
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Rene Russo BCPS | President, Chief Executive Officer & Director | 1975 | $1,158,176 USD |
| Christopher Frankenfield | Chief Financial Officer & Chief Operating Officer | 1982 | $941,594 USD |
| Katarina Luptakova | Chief Medical Officer | 1976 | $691,670 USD |
| Caroline Hensley | Chief Legal Officer | – | – |
| Kevin Brennan | Senior Vice President of Finance & Accounting | 1970 | – |
| Nathan McBride | Chief Information Officer | – | – |
| Ruth du Moulin | Senior Vice President of Medical Affairs | – | – |
| Scott Coleman | Chief Development Officer | – | – |
| Uli Bialucha | Chief Scientific Officer | – | – |